Literature DB >> 28331724

Male Breast Cancer.

Metin Yalaza1, Aydın İnan2, Mikdat Bozer3.   

Abstract

Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancer diagnoses worldwide. Although breast carcinomas share certain characteristics in both genders, there are notable differences. Most studies on men with breast cancer are very small. Thus, most data on male breast cancer are derived from studies on females. However, when a number of these small studies are grouped together, we can learn more from them. This review emphasizes the incidence, etiology, clinical features, diagnosis, treatment, pathology, survival, and prognostic factors related to MBC.

Entities:  

Keywords:  Breast cancer; male gender; review

Year:  2016        PMID: 28331724      PMCID: PMC5351429          DOI: 10.5152/tjbh.2015.2711

Source DB:  PubMed          Journal:  J Breast Health        ISSN: 1306-0945


  98 in total

1.  [Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases].

Authors:  A-S Oger; M Boukerrou; B Cutuli; L Campion; E Rousseau; E Bussières; P Raro; J-M Classe
Journal:  Gynecol Obstet Fertil       Date:  2015-03-26

2.  Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996.

Authors:  P E Goss; C Reid; M Pintilie; R Lim; N Miller
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

3.  Occupational exposures associated with male breast cancer.

Authors:  P F Rosenbaum; J E Vena; M A Zielezny; A M Michalek
Journal:  Am J Epidemiol       Date:  1994-01-01       Impact factor: 4.897

Review 4.  Radiography of gynecomastia and other disorders of the male breast.

Authors:  L G Michels; R H Gold; R D Arndt
Journal:  Radiology       Date:  1977-01       Impact factor: 11.105

5.  Molecular markers in male breast carcinoma.

Authors:  D Rayson; C Erlichman; V J Suman; P C Roche; L E Wold; J N Ingle; J H Donohue
Journal:  Cancer       Date:  1998-11-01       Impact factor: 6.860

Review 6.  Male breast cancer: a special therapeutic problem. Anything new? (Review).

Authors:  Roberto Gennari; Giuseppe Curigliano; Barbara A Jereczek-Fossa; Stefano Zurrida; Giuseppe Renne; Mattia Intra; Viviana Galimberti; Alberto Luini; Roberto Orecchia; Giuseppe Viale; Aron Goldhrisch; Umberto Veronesi
Journal:  Int J Oncol       Date:  2004-03       Impact factor: 5.650

7.  Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening.

Authors:  U J Lee; J S Jones
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-05-27       Impact factor: 5.554

Review 8.  Male breast cancer: results of the treatments and prognostic factors in 397 cases.

Authors:  B Cutuli; M Lacroze; J M Dilhuydy; M Velten; B De Lafontan; C Marchal; M Resbeut; Y Graic; F Campana; V Moncho-Bernier
Journal:  Eur J Cancer       Date:  1995-11       Impact factor: 9.162

Review 9.  Second cancers in patients with male breast cancer: a literature review.

Authors:  Tal Grenader; Anthony Goldberg; Linda Shavit
Journal:  J Cancer Surviv       Date:  2008-04-01       Impact factor: 4.442

Review 10.  Male breast cancer: is the scenario changing.

Authors:  Kaiyumars B Contractor; Kanchan Kaur; Gabriel S Rodrigues; Dhananjay M Kulkarni; Hemant Singhal
Journal:  World J Surg Oncol       Date:  2008-06-16       Impact factor: 2.754

View more
  18 in total

1.  A Rare Case of Bilateral Synchronous Male Breast Cancer: A Multimodality Approach.

Authors:  Cihan Özgür; Baran Serdar Sunal; Nermin Tunçbilek
Journal:  Eur J Breast Health       Date:  2022-04-01

2.  Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients.

Authors:  İzzet Doğan; Esra Aydın; Hülya Yazıcı; Pınar Saip
Journal:  Eur J Breast Health       Date:  2022-10-01

Review 3.  Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer: a comprehensive update.

Authors:  Partha Roy; Srija Sur; Suvadra Das; Wong Tin Wui
Journal:  Breast Cancer       Date:  2022-05-16       Impact factor: 3.307

Review 4.  A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer.

Authors:  Franklyn De Silva; Jane Alcorn
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

5.  Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial.

Authors:  Roberta Caputo; Alessandra Fabi; Emanuela Romagnoli; Editta Baldini; Donatella Grasso; Nicola Fenderico; Andrea Michelotti
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-10-18

6.  Nomograms for predicting overall and cancer-specific survival in patients with papillary renal cell carcinoma: a population-based study using SEER database.

Authors:  Haicui Yan; Xiyi Wei; Aimin Wu; Yeqin Sha; Xiao Li; Feng Qi
Journal:  Transl Androl Urol       Date:  2020-06

7.  A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery.

Authors:  Xin Chai; Mei-Yang Sun; Hong-Yao Jia; Min Wang; Ling Cao; Zhi-Wen Li; Dun-Wei Wang
Journal:  PeerJ       Date:  2019-10-14       Impact factor: 2.984

Review 8.  Drug repurposing for breast cancer therapy: Old weapon for new battle.

Authors:  Sadhna Aggarwal; Sumit Singh Verma; Sumit Aggarwal; Subash Chandra Gupta
Journal:  Semin Cancer Biol       Date:  2019-09-21       Impact factor: 15.707

9.  Spatial distribution of breast cancer in Sudan 2010-2016.

Authors:  Marwa Maweya Abdelbagi Elbasheer; Ayah Galal Abdelrahman Alkhidir; Siham Mohammed Awad Mohammed; Areej Abuelgasim Hassan Abbas; Aisha Osman Mohamed; Isra Mahgoub Bereir; Hiba Reyad Abdalazeez; Mounkaila Noma
Journal:  PLoS One       Date:  2019-09-16       Impact factor: 3.240

10.  Male Breast Cancer: Reevaluate Our Opinion.

Authors:  Santosh Kale; Rajmohan Rammohan; Vilma Vas; Chris Elsayad
Journal:  Case Rep Oncol Med       Date:  2020-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.